**Supplementary material**

**S1.** The number needed to harm (and its 95% confidence intervals) for VEGFR TKIs using the complementary outcome for 11 adverse events

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   | Overall | Axitinib | Levantinib | Nintedanib | Pazopanib | Regorafenib | Sorafenib | Sunitinib | Vandetanib |
| Thrombotic | n/a | - | - | n/a | n/a | n/a | n/a | n/a | n/a |
| Arterial thrombotic | n/a | n/a | - | n/a | **26 (15-132)** | - | - | - | - |
| Myocardial infarction | n/a | - | n/a | n/a | n/a | - | n/a | n/a | n/a |
| Stroke | n/a | n/a | n/a | n/a | n/a | - | n/a | n/a | n/a |
| Venous thrombotic | n/a | n/a | n/a | n/a | n/a | - | n/a | n/a | n/a |
| Pulmonary embolism | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Bleeding | n/a | n/a | - | **28 (17-104)** | - | n/a | n/a | **2 (1-4)** | n/a |
| Thrombocytopenia | n/a | n/a | n/a | n/a | n/a | **12 (10-15)** | n/a | n/a | n/a |
| Left ventricular dysfunction | n/a | n/a | - | - | n/a | n/a | n/a | n/a | n/a |
| QTc interval prolongation | n/a | n/a | - | - | n/a | - | - | n/a | n/a |
| Hypertension | **15 (10-40)** | n/a | **2 (1-3)** | n/a | **4 (3-10)** | **4 (4-9)** | **12 (17-117)** | n/a | n/a |
| *n/a* not applicable, no association between the exposure (i.e. VEGFR TKIs) and the outcome (i.e. adverse events) |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| A) Thrombotic event | B) Arterial thrombotic event | C) Myocardial infarction | D) Stroke | E) Venous thrombotic event | F) Pulmonary embolism |
| G) Bleeding | H) Thrombocytopenia | I) Left ventricular dysfunction | J) QTc prolongation | K) Hypertension |  |
| **S2.** Doi plot and LFK index value a) thrombotic; b) arterial thrombotic; c) myocardial infarction; d) stroke; e) venous thrombotic; f) pulmonary embolism; g) bleeding; h) thrombocytopenia; i) left ventricular dysfunction; j) QTc interval prolongation; and k) hypertension |